Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | MPO | P05164 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987403 | 0.89 | LMNA (0.67) | POLBLMNAMAPTSOAT1 | |
| SCHEMBL4987412 | 0.88 | LMNA (0.65) | POLBLMNAMAPTSOAT1 | |
| SCHEMBL4986541 | 0.87 | LMNA (0.64) | POLBLMNAMAPTSOAT1 | |
| SCHEMBL4983244 | 0.87 | LMNA (0.64) | POLBLMNAMAPTSOAT1 | |
| SCHEMBL4983723 | 0.87 | LMNA (0.64) | POLBLMNAMAPTSOAT1 | |
| SCHEMBL4983652 | 0.87 | LMNA (0.64) | POLBLMNAMAPTSOAT1 | |
| SCHEMBL4984778 | 0.85 | MPO (0.62) | POLBMPOCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14970915 | 0.79 | POLB (0.67) | POLBMPOCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4985807 | 0.79 | POLB (0.69) | POLBCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4990028 | 0.79 | NPC1 (0.69) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414066-B2 | Amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7393866-B2 | Amide compounds and medications containing the same | KOWA COMPANY, LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| EP-0979823-B1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-6849647-B1 | Amide compounds and medications containing the same technical field | KOWA COMPANY, LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| EP-0979823-A1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | ACAT2, SULT2A1, ACAT1 | POLB 4033/4885MPO 3119/4885CYP1A2 392/4885 |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | ACAT2, SULT2A1, ACAT1 | POLB 4025/4885MPO 3018/4885CYP1A2 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.